Repare Therapeutics Statistics
Total Valuation
RPTX has a market cap or net worth of $114.24 million. The enterprise value is $1.56 million.
| Market Cap | 114.24M |
| Enterprise Value | 1.56M |
Important Dates
The next estimated earnings date is Monday, March 2, 2026, before market open.
| Earnings Date | Mar 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RPTX has 43.11 million shares outstanding. The number of shares has increased by 1.02% in one year.
| Current Share Class | 43.11M |
| Shares Outstanding | 43.11M |
| Shares Change (YoY) | +1.02% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 27.75% |
| Float | 22.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.54 |
| Forward PS | 14.88 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.71, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.71 |
| Quick Ratio | 10.40 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.78% and return on invested capital (ROIC) is -3,560.00%.
| Return on Equity (ROE) | -49.78% |
| Return on Assets (ROA) | -29.72% |
| Return on Invested Capital (ROIC) | -3,560.00% |
| Return on Capital Employed (ROCE) | -68.80% |
| Weighted Average Cost of Capital (WACC) | 9.51% |
| Revenue Per Employee | $92,016 |
| Profits Per Employee | -$559,690 |
| Employee Count | 129 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RPTX has paid $763,000 in taxes.
| Income Tax | 763,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +116.42% in the last 52 weeks. The beta is 0.96, so RPTX's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +116.42% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 73.23 |
| Average Volume (20 Days) | 1,016,957 |
Short Selling Information
The latest short interest is 194,336, so 0.45% of the outstanding shares have been sold short.
| Short Interest | 194,336 |
| Short Previous Month | 352,361 |
| Short % of Shares Out | 0.45% |
| Short % of Float | 0.85% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, RPTX had revenue of $11.87 million and -$72.20 million in losses. Loss per share was -$1.69.
| Revenue | 11.87M |
| Gross Profit | 47.88M |
| Operating Income | -79.21M |
| Pretax Income | -71.44M |
| Net Income | -72.20M |
| EBITDA | -76.46M |
| EBIT | -79.21M |
| Loss Per Share | -$1.69 |
Balance Sheet
The company has $112.60 million in cash and $342,000 in debt, with a net cash position of $112.26 million or $2.60 per share.
| Cash & Cash Equivalents | 112.60M |
| Total Debt | 342,000 |
| Net Cash | 112.26M |
| Net Cash Per Share | $2.60 |
| Equity (Book Value) | 115.13M |
| Book Value Per Share | 2.68 |
| Working Capital | 112.81M |
Cash Flow
| Operating Cash Flow | -70.15M |
| Capital Expenditures | n/a |
| Free Cash Flow | -70.15M |
| FCF Per Share | -$1.63 |
Margins
| Gross Margin | 403.40% |
| Operating Margin | -667.31% |
| Pretax Margin | -601.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.02% |
| Shareholder Yield | -1.02% |
| Earnings Yield | -63.43% |
| FCF Yield | -61.63% |
Analyst Forecast
The average price target for RPTX is $3.00, which is 13.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 13.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RPTX has an Altman Z-Score of -2.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.07 |
| Piotroski F-Score | 3 |